nach oben

Current Geriatrics Reports

Erschienen in:

09.11.2020 | Nutrition, Obesity, and Diabetes (SML Ribeiro, Section Editor)

Nutrition and Diabetes in the Context of Inflammaging

verfasst von: Sandra Maria Lima Ribeiro, S. S. M. Fernandez, M. M. Rogero

Erschienen in: Current Geriatrics Reports | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

To update the concepts of inflammaging and the development of insulin resistance and type 2 diabetes mellitus (T2DM); to summarize some related nutritional aspects.

Recent Findings

Inflammaging is a complex network of aging-related changes, which are associated with immunosenescence and metainflammation (the inflammation originated outside the immune system which may include the gut environment, adipose tissue, or self-molecules generated in different types of cells). The inflammatory status increases insulin resistance and, consequently, the risk of T2DM. Dietary patterns, including foods, nutrients, and bioactive compounds, can modulate inflammatory pathways and may contribute positively or negatively to inflammatory status and prevention or management to T2DM. Some examples of these dietary components are fatty acids, phytochemicals, salt, carbohydrates, among others. Studies aiming at caloric restriction (caloric restriction per se [CR] or intermittent fasting [IR]) have shown promising results. However, they need precaution when applied to older adults.

Summary

Dietary intervention on inflammaging and T2DM still deserves further studies related to its application in clinical practice. Clinical and epidemiological investigations of diet, its association with inflammaging, and T2DM should integrate different omic approaches in order to understand these complex relationships.

Franceschi C, Garagnani P, Vitale G, Capri M, Salvioli S. Inflammaging and “garb-aging”. Trends Endocrinol Metab. 2017;28:199–212. https://doi.org/10.1016/j.tem.2016.09.005.CrossRefPubMed

Salvioli S, Monti D, Lanzarini C, Conte M, Pirazzini C, Giulia Bacalini M, et al. Immune system, cell senescence, aging and longevity - inflamm-aging reappraised. Curr Pharm Des. 2013;19:1675–9. https://doi.org/10.2174/1381612811319090015.CrossRefPubMed

•• Franceschi C, Garagnani P, Parini P, Giuliani C, Santoro A. Inflammaging: a new immune-metabolic viewpoint for age-related diseases. Nat Rev Endocrinol. 2018;14:576–90. https://doi.org/10.1038/s41574-018-0059-4Updated concepts of inflammaging.CrossRefPubMed

Franceschi C, Bonafè M, Valensin S, Olivieri F, De Luca M, Ottaviani E, et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci. 2000;908:244–54. https://doi.org/10.1111/j.1749-6632.2000.tb06651.x.CrossRefPubMed

McPhee JB, Schertzer JD. Immunometabolism of obesity and diabetes: microbiota link compartmentalized immunity in the gut to metabolic tissue inflammation. Clin Sci. 2015;129:1083–96. https://doi.org/10.1042/CS20150431.CrossRef

• Oguntibeju OO. Type 2 diabetes mellitus, oxidative stress and inflammation: examining the links. Int J Physiol Pathophysiol Pharmacol. 2019;11:45–63 Mechanisms associating diabetes and inflammation.PubMedPubMedCentral

Calle MC, Fernandez ML. Inflammation and type 2 diabetes. Diabetes Metab. 2012;38:183–91. https://doi.org/10.1016/j.diabet.2011.11.006.CrossRefPubMed

Lontchi-Yimagou E, Sobngwi E, Matsha TE, Kengne AP. Diabetes mellitus and inflammation. Curr Diab Rep. 2013;13:435–44. https://doi.org/10.1007/s11892-013-0375-y.CrossRefPubMed

Bodogai M, O’Connell J, Kim K, Kim Y, Moritoh K, Chen C, et al. Commensal bacteria contribute to insulin resistance in aging by activating innate B1a cells. Sci Transl Med. 2018;10:eaat4271. https://doi.org/10.1126/scitranslmed.aat4271.CrossRefPubMedPubMedCentral

10.

Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14:88–98. https://doi.org/10.1038/nrendo.2017.151.CrossRefPubMed

11.

Shaw AC, Joshi S, Greenwood H, Panda A, Lord JM. Aging of the innate immune system. Curr Opin Immunol. 2010;22:507–13. https://doi.org/10.1016/j.coi.2010.05.003.CrossRefPubMedPubMedCentral

12.

Hazeldine J, Lord JM. Innate immunesenescence: underlying mechanisms and clinical relevance. Biogerontology. 2015;16:187–201. https://doi.org/10.1007/s10522-014-9514-3.CrossRefPubMed

13.

Fulop T, Kotb R, Fortin CF, Pawelec G, De Angelis F, Larbi A. Potential role of immunosenescence in cancer development. Ann N Y Acad Sci. 2010;1197:158–65. https://doi.org/10.1111/j.1749-6632.2009.05370.x.CrossRefPubMed

14.

Fulop T, Larbi A, Dupuis G, Le Page A, Frost EH, Cohen AA, et al. Immunosenescence and inflamm-aging as two sides of the same coin: friends or foes? Front Immunol. 2018;8. https://doi.org/10.3389/fimmu.2017.01960.

15.

Alexaki V-I, Notas G, Pelekanou V, Kampa M, Valkanou M, Theodoropoulos P, et al. Adipocytes as immune cells: differential expression of TWEAK, BAFF, and APRIL and their receptors (Fn14, BAFF-R, TACI, and BCMA) at different stages of normal and pathological adipose tissue development. J Immunol. 2009;183:5948–56. https://doi.org/10.4049/jimmunol.0901186.CrossRefPubMed

16.

Zorena K, Jachimowicz-Duda O, Ślęzak D, Robakowska M, Mrugacz M. Adipokines and obesity. Potential link to metabolic disorders and chronic complications. Int J Mol Sci. 2020;21:3570. https://doi.org/10.3390/ijms21103570.CrossRefPubMedCentral

17.

Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008;8:958–69. https://doi.org/10.1038/nri2448.CrossRefPubMedPubMedCentral

18.

Frühbeck G, Catalán V, Rodríguez A, Ramírez B, Becerril S, Salvador J, et al. Involvement of the leptin-adiponectin axis in inflammation and oxidative stress in the metabolic syndrome. Sci Rep. 2017;7:6619. https://doi.org/10.1038/s41598-017-06997-0.CrossRefPubMedPubMedCentral

19.

Halcox JP, Roy C, Tubach F, Banegas JR, Dallongeville J, De Backer G, et al. C-reactive protein levels in patients at cardiovascular risk: EURIKA study. BMC Cardiovasc Disord. 2014;14:25. https://doi.org/10.1186/1471-2261-14-25.CrossRefPubMedPubMedCentral

20.

Daniele G, Guardado Mendoza R, Winnier D, Fiorentino TV, Pengou Z, Cornell J, et al. The inflammatory status score including IL-6, TNF-α, osteopontin, fractalkine, MCP-1 and adiponectin underlies whole-body insulin resistance and hyperglycemia in type 2 diabetes mellitus. Acta Diabetol. 2014;51:123–31. https://doi.org/10.1007/s00592-013-0543-1.CrossRefPubMed

21.

Livshits G, Kalinkovich A. Inflammaging as a common ground for the development and maintenance of sarcopenia, obesity, cardiomyopathy and dysbiosis. Ageing Res Rev. 2019;56:100980. https://doi.org/10.1016/j.arr.2019.100980.CrossRefPubMed

22.

Eguchi K, Nagai R. Islet inflammation in type 2 diabetes and physiology. J Clin Invest. 2017;127:14–23. https://doi.org/10.1172/JCI88877.CrossRefPubMedPubMedCentral

23.

Abbatecola AM, Paolisso G. Is there a relationship between insulin resistance and frailty syndrome? Curr Pharm Des. 2008;14:405–10. https://doi.org/10.2174/138161208783497750.CrossRefPubMed

24.

Boirie Y. Physiopathological mechanism of sarcopenia. J Nutr Health Aging. 2009;13:717–23.CrossRefPubMed

25.

Castanon N, Luheshi G, Layé S. Role of neuroinflammation in the emotional and cognitive alterations displayed by animal models of obesity. Front Neurosci. 2015;9:229. https://doi.org/10.3389/fnins.2015.00229.CrossRefPubMedPubMedCentral

26.

Di Benedetto S, Müller L, Wenger E, Düzel S, Pawelec G. Contribution of neuroinflammation and immunity to brain aging and the mitigating effects of physical and cognitive interventions. Neurosci Biobehav Rev. 2017;75:114–28. https://doi.org/10.1016/j.neubiorev.2017.01.044.CrossRefPubMed

27.

Lee YS, Wollam J, Olefsky JM. An integrated view of immunometabolism. Cell. Elsevier Inc. 2018;172:22–40. https://doi.org/10.1016/j.cell.2017.12.025.CrossRefPubMedPubMedCentral

28.

Fang C, Xu H, Guo S, Mertens-Talcott SU, Sun Y. Ghrelin signaling in immunometabolism and inflamm-aging. Adv Exp Med Biol. 2018;1090:165–82. https://doi.org/10.1007/978-981-13-1286-1_9.CrossRefPubMed

29.

Amsterdam D, Ostrov BE. The impact of the microbiome on immunosenescence. Immunol Investig. 2018;47:801–11. https://doi.org/10.1080/08820139.2018.1537570.CrossRef

30.

Tiihonen K, Ouwehand AC, Rautonen N. Human intestinal microbiota and healthy ageing. Ageing Res Rev. 2010;9:107–16. https://doi.org/10.1016/j.arr.2009.10.004.CrossRefPubMed

31.

André, Laugerette, Féart. Metabolic endotoxemia: a potential underlying mechanism of the relationship between dietary fat intake and risk for cognitive impairments in humans? Nutrients. 2019;11:1887. https://doi.org/10.3390/nu11081887.CrossRefPubMedCentral

32.

Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes. 2008;57:1470–81. https://doi.org/10.2337/db07-1403.CrossRefPubMed

33.

Kamada N, Chen GY, Inohara N, Núñez G. Control of pathogens and pathobionts by the gut microbiota. Nat Immunol. 2013;14(7):685–90. https://doi.org/10.1038/ni.2608.CrossRefPubMedPubMedCentral

34.

Brown J, Wang H, Hajishengallis GN, Martin M. TLR-signaling networks: an integration of adaptor molecules, kinases, and cross-talk. J Dent Res. 2011;90:417–27. https://doi.org/10.1177/0022034510381264.CrossRefPubMedPubMedCentral

35.

Salminen A, Kaarniranta K, Kauppinen A. Inflammaging: disturbed interplay between autophagy and inflammasomes. Aging (Albany NY). 2012;4:166–75. https://doi.org/10.18632/aging.100444.CrossRef

36.

Shalini S, Dorstyn L, Dawar S, Kumar S. Old, new and emerging functions of caspases. Cell Death Differ. 2015;22:526–39. https://doi.org/10.1038/cdd.2014.216.CrossRefPubMed

37.

Xia S, Zhang X, Zheng S, Khanabdali R, Kalionis B, Wu J, et al. An update on inflamm-aging: mechanisms, prevention, and treatment. J Immunol Res. 2016;2016:8426874–12. https://doi.org/10.1155/2016/8426874.CrossRefPubMedPubMedCentral

38.

Kalupahana NS, Moustaid-Moussa N, Claycombe KJ. Immunity as a link between obesity and insulin resistance. Mol Asp Med. 2012;33:26–34. https://doi.org/10.1016/j.mam.2011.10.011.CrossRef

39.

Yang J, Park Y, Zhang H, Xu X, Laine GA, Dellsperger KC, et al. Feed-forward signaling of TNF-alpha and NF-kappaB via IKK-beta pathway contributes to insulin resistance and coronary arteriolar dysfunction in type 2 diabetic mice. Am J Physiol Heart Circ Physiol. 2009;296:H1850–8. https://doi.org/10.1152/ajpheart.01199.2008.CrossRefPubMedPubMedCentral

40.

Panickar KS, Jewell DE. The beneficial role of anti-inflammatory dietary ingredients in attenuating markers of chronic low-grade inflammation in aging. Horm Mol Biol Clin Investig. 2015;23:59–70. https://doi.org/10.1515/hmbci-2015-0017.CrossRefPubMed

41.

Kirwan AM, Lenighan YM, O’Reilly ME, McGillicuddy FC, Roche HM. Nutritional modulation of metabolic inflammation. Biochem Soc Trans. 2017;45:979–85. https://doi.org/10.1042/BST20160465.CrossRefPubMed

42.

Calle MC, Andersen CJ. Assessment of dietary patterns represents a potential, yet variable, measure of inflammatory status: a review and update. Dis Markers. 2019;2019:3102870–13. https://doi.org/10.1155/2019/3102870.CrossRefPubMedPubMedCentral

43.

Bonaccio M, Di Castelnuovo A, Costanzo S, Gialluisi A, Persichillo M, Cerletti C, et al. Mediterranean diet and mortality in the elderly: a prospective cohort study and a meta-analysis. Br J Nutr. 2018;120:841–54. https://doi.org/10.1017/S0007114518002179.CrossRefPubMed

44.

•• Nowson CA, Service C, Appleton J, Grieger JA. The impact of dietary factors on indices of chronic disease in older people: a systematic review. J Nutr Health Aging. 2018;22:282–96. https://doi.org/10.1007/s12603-017-0920-5This review brings together different aspects of diet on the development of chronic diseases in aging.CrossRefPubMed

45.

Davis C, Bryan J, Hodgson J, Murphy K. Definition of the Mediterranean diet; a literature review. Nutrients. 2015;7:9139–53. https://doi.org/10.3390/nu7115459.CrossRefPubMedPubMedCentral

46.

Tuttolomondo A, Simonetta I, Daidone M, Mogavero A, Ortello A, Pinto A. Metabolic and vascular effect of the Mediterranean diet. Int J Mol Sci. 2019;20. https://doi.org/10.3390/ijms20194716.

47.

Norde MM, Collese TS, Giovannucci E, Rogero MM. A posteriori dietary patterns and their association with systemic low-grade inflammation in adults: a systematic review and meta-analysis. Nutr Rev. 2020. https://doi.org/10.1093/nutrit/nuaa010.

48.

Lee JY, Sohn KH, Rhee SH, Hwang D. Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. J Biol Chem. 2001;276:16683–9. https://doi.org/10.1074/jbc.M011695200.CrossRefPubMed

49.

Caricilli AM, Nascimento PH, Pauli JR, Tsukumo DML, Velloso LA, Carvalheira JB, et al. Inhibition of toll-like receptor 2 expression improves insulin sensitivity and signaling in muscle and white adipose tissue of mice fed a high-fat diet. J Endocrinol. 2008;199:399–406. https://doi.org/10.1677/JOE-08-0354.CrossRefPubMed

50.

Calder PC, Ahluwalia N, Brouns F, Buetler T, Clement K, Cunningham K, et al. Dietary factors and low-grade inflammation in relation to overweight and obesity. Br J Nutr. 2011;106:S5–78. https://doi.org/10.1017/S0007114511005460.CrossRefPubMed

51.

Hwang DH, Kim J-A, Lee JY. Mechanisms for the activation of Toll-like receptor 2/4 by saturated fatty acids and inhibition by docosahexaenoic acid. Eur J Pharmacol. 2016;785:24–35. https://doi.org/10.1016/j.ejphar.2016.04.024.CrossRefPubMedPubMedCentral

52.

Oh DY, Talukdar S, Bae EJ, Imamura T, Morinaga H, Fan W, et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell. 2010;142:687–98. https://doi.org/10.1016/j.cell.2010.07.041.CrossRefPubMedPubMedCentral

53.

Mantzaris MD, Tsianos EV, Galaris D. Interruption of triacylglycerol synthesis in the endoplasmic reticulum is the initiating event for saturated fatty acid-induced lipotoxicity in liver cells. FEBS J. 2011;278:519–30. https://doi.org/10.1111/j.1742-4658.2010.07972.x.CrossRefPubMed

54.

Leamy AK, Egnatchik RA, Shiota M, Ivanova PT, Myers DS, Brown HA, et al. Enhanced synthesis of saturated phospholipids is associated with ER stress and lipotoxicity in palmitate treated hepatic cells. J Lipid Res. 2014;55:1478–88. https://doi.org/10.1194/jlr.M050237.CrossRefPubMedPubMedCentral

55.

Milenkovic D, Jude B, Morand C. miRNA as molecular target of polyphenols underlying their biological effects. Free Radic Biol Med. 2013;64:40–51. https://doi.org/10.1016/j.freeradbiomed.2013.05.046.CrossRefPubMed

56.

Zhou Y, Zhang T, Wang X, Wei X, Chen Y, Guo L, et al. Curcumin modulates macrophage polarization through the inhibition of the toll-like receptor 4 expression and its signaling pathways. Cell Physiol Biochem. 2015;36:631–41. https://doi.org/10.1159/000430126.CrossRefPubMed

57.

Trujillo J, Granados-Castro LF, Zazueta C, Andérica-Romero AC, Chirino YI, Pedraza-Chaverrí J. Mitochondria as a target in the therapeutic properties of curcumin. Arch Pharm (Weinheim). 2014;347:873–84. https://doi.org/10.1002/ardp.201400266.CrossRef

58.

Shehzad A, Rehman G, Lee YS. Curcumin in inflammatory diseases. BioFactors. 2013;39:69–77. https://doi.org/10.1002/biof.1066.CrossRefPubMed

59.

Karimian MS, Pirro M, Majeed M, Sahebkar A. Curcumin as a natural regulator of monocyte chemoattractant protein-1. Cytokine Growth Factor Rev. 2017;33:55–63. https://doi.org/10.1016/j.cytogfr.2016.10.001.CrossRefPubMed

60.

Epstein J, Sanderson IR, Macdonald TT. Curcumin as a therapeutic agent: the evidence from in vitro, animal and human studies. Br J Nutr. 2010;103:1545–57. https://doi.org/10.1017/S0007114509993667.CrossRefPubMed

61.

Yang H, Xu W, Zhou Z, Liu J, Li X, Chen L, et al. Curcumin attenuates urinary excretion of albumin in type II diabetic patients with enhancing nuclear factor erythroid-derived 2-like 2 (Nrf2) system and repressing inflammatory signaling efficacies. Exp Clin Endocrinol Diabetes. 2015;123:360–7. https://doi.org/10.1055/s-0035-1545345.CrossRefPubMed

62.

Magyar K, Halmosi R, Palfi A, Feher G, Czopf L, Fulop A, et al. Cardioprotection by resveratrol: a human clinical trial in patients with stable coronary artery disease. Clin Hemorheol Microcirc. 2012;50:179–87. https://doi.org/10.3233/CH-2011-1424.CrossRefPubMed

63.

Poulsen MM, Fjeldborg K, Ornstrup MJ, Kjær TN, Nøhr MK, Pedersen SB. Resveratrol and inflammation: challenges in translating pre-clinical findings to improved patient outcomes. Biochim Biophys Acta. 1852;2015:1124–36. https://doi.org/10.1016/j.bbadis.2014.12.024.CrossRef

64.

Pektas MB, Koca HB, Sadi G, Akar F. Dietary fructose activates insulin signaling and inflammation in adipose tissue: modulatory role of resveratrol. Biomed Res Int. 2016;2016:8014252–10. https://doi.org/10.1155/2016/8014252.CrossRefPubMedPubMedCentral

65.

Timmers S, Konings E, Bilet L, Houtkooper RH, van de Weijer T, Goossens GH, et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011;14:612–22. https://doi.org/10.1016/j.cmet.2011.10.002.CrossRefPubMed

66.

Kleinewietfeld M, Manzel A, Titze J, Kvakan H, Yosef N, Linker RA, et al. Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells. Nature. 2013;496(7446):518–22. https://doi.org/10.1038/nature11868.CrossRefPubMedPubMedCentral

67.

Wu J, Liu X, Lai G, Yang X, Wang L, Zhao Y. Synergistical effect of 20-HETE and high salt on NKCC2 protein and blood pressure via ubiquitin-proteasome pathway. Hum Genet. 2013;132(2):179–87. https://doi.org/10.1007/s00439-012-1238-3.CrossRefPubMed

68.

Binger KJ, Gebhardt M, Heinig M, Rintisch C, Schroeder A, Neuhofer W, et al. High salt reduces the activation of IL-4- and IL-13-stimulated macrophages. J Clin Invest. 2015;125(11):4223–38. https://doi.org/10.1172/JCI80919.CrossRefPubMedPubMedCentral

69.

Holub I, Gostner A, Theis S, Nosek L, Kudlich T, Melcher R, et al. Novel findings on the metabolic effects of the low glycaemic carbohydrate isomaltulose (Palatinose). Br J Nutr. 2010;103:1730–7. https://doi.org/10.1017/S0007114509993874.CrossRefPubMedPubMedCentral

70.

Nauck MA, Meier JJ. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. Lancet Diabetes Endocrinol. 2016;4:525–36. https://doi.org/10.1016/S2213-8587(15)00482-9.CrossRefPubMed

71.

Holst JJ. On the physiology of GIP and GLP-1. Horm Metab Res. 2004;36:747–54. https://doi.org/10.1055/s-2004-826158.CrossRefPubMed

72.

Timper K, Grisouard J, Sauter NS, Herzog-Radimerski T, Dembinski K, Peterli R, et al. Glucose-dependent insulinotropic polypeptide induces cytokine expression, lipolysis, and insulin resistance in human adipocytes. Am J Physiol Metab. 2013;304:E1–13. https://doi.org/10.1152/ajpendo.00100.2012.CrossRef

73.

Chen S, Okahara F, Osaki N, Shimotoyodome A. Increased GIP signaling induces adipose inflammation via a HIF-1α-dependent pathway and impairs insulin sensitivity in mice. Am J Physiol Endocrinol Metab. 2015;308:E414–25. https://doi.org/10.1152/ajpendo.00418.2014.CrossRefPubMed

74.

Gögebakan Ö, Osterhoff MA, Schüler R, Pivovarova O, Kruse M, Seltmann A-C, et al. GIP increases adipose tissue expression and blood levels of MCP-1 in humans and links high energy diets to inflammation: a randomised trial. Diabetologia. 2015;58:1759–68. https://doi.org/10.1007/s00125-015-3618-4.CrossRefPubMed

75.

Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490:55–60. https://doi.org/10.1038/nature11450.CrossRefPubMed

76.

Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell. 2016;165:1332–45. https://doi.org/10.1016/j.cell.2016.05.041.CrossRefPubMed

77.

Singh N, Thangaraju M, Prasad PD, Martin PM, Lambert NA, Boettger T, et al. Blockade of dendritic cell development by bacterial fermentation products butyrate and propionate through a transporter (Slc5a8)-dependent inhibition of histone deacetylases. J Biol Chem. 2010;285:27601–8. https://doi.org/10.1074/jbc.M110.102947.CrossRefPubMedPubMedCentral

78.

Kaiko GE, Ryu SH, Koues OI, Collins PL, Solnica-Krezel L, Pearce EJ, et al. The colonic crypt protects stem cells from microbiota-derived metabolites. Cell. 2016;165:1708–20. https://doi.org/10.1016/j.cell.2016.05.018.CrossRefPubMedPubMedCentral

79.

Levy M, Blacher E, Elinav E. Microbiome, metabolites and host immunity. Curr Opin Microbiol. 2017;35:8–15. https://doi.org/10.1016/j.mib.2016.10.003.CrossRefPubMed

80.

Wang B, Morinobu A, Horiuchi M, Liu J, Kumagai S. Butyrate inhibits functional differentiation of human monocyte-derived dendritic cells. Cell Immunol. 253:54–8. https://doi.org/10.1016/j.cellimm.2008.04.016.

81.

Millard AL, Mertes PM, Ittelet D, Villard F, Jeannesson P, Bernard J. Butyrate affects differentiation, maturation and function of human monocyte-derived dendritic cells and macrophages. Clin Exp Immunol. 2002;130:245–55. https://doi.org/10.1046/j.0009-9104.2002.01977.x.CrossRefPubMedPubMedCentral

82.

Berndt BE, Zhang M, Owyang SY, Cole TS, Wang TW, Luther J, et al. Butyrate increases IL-23 production by stimulated dendritic cells. Am J Physiol Gastrointest Liver Physiol. 2012;303:G1384–92. https://doi.org/10.1152/ajpgi.00540.2011.CrossRefPubMedPubMedCentral

83.

Segal AW. How neutrophils kill microbes. Annu Rev Immunol. 2005;23:197–223. https://doi.org/10.1146/annurev.immunol.23.021704.115653.CrossRefPubMedPubMedCentral

84.

Vinolo MAR, Rodrigues HG, Hatanaka E, Sato FT, Sampaio SC, Curi R. Suppressive effect of short-chain fatty acids on production of proinflammatory mediators by neutrophils. J Nutr Biochem. 2011;22:849–55. https://doi.org/10.1016/j.jnutbio.2010.07.009.CrossRefPubMed

85.

Park J, Kim M, Kang SG, Jannasch AH, Cooper B, Patterson J, et al. Short-chain fatty acids induce both effector and regulatory T cells by suppression of histone deacetylases and regulation of the mTOR-S6K pathway. Mucosal Immunol. 2015;8:80–93. https://doi.org/10.1038/mi.2014.44.CrossRefPubMed

86.

Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly-Y M, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science. 2013;341:569–73. https://doi.org/10.1126/science.1241165.CrossRefPubMed

87.

Caro-Maldonado A, Wang R, Nichols AG, Kuraoka M, Milasta S, Sun LD, et al. Metabolic reprogramming is required for antibody production that is suppressed in anergic but exaggerated in chronically BAFF-exposed B cells. J Immunol. 2014;192:3626–36. https://doi.org/10.4049/jimmunol.1302062.CrossRefPubMed

88.

Kim M, Qie Y, Park J, Kim CH. Gut microbial metabolites fuel host antibody responses. Cell Host Microbe. 2016;20(2):202–14. https://doi.org/10.1016/j.chom.2016.07.001.CrossRefPubMedPubMedCentral

89.

Speakman JR, Mitchell SE, Mazidi M. Calories or protein? The effect of dietary restriction on lifespan in rodents is explained by calories alone. Exp Gerontol. 2016;86:28–38. https://doi.org/10.1016/j.exger.2016.03.011.CrossRefPubMed

90.

Cioffi I, Evangelista A, Ponzo V, Ciccone G, Soldati L, Santarpia L, et al. Intermittent versus continuous energy restriction on weight loss and cardiometabolic outcomes: a systematic review and meta-analysis of randomized controlled trials. J Transl Med. 2018;16:371. https://doi.org/10.1186/s12967-018-1748-4.CrossRefPubMedPubMedCentral

91.

Horne BD, Muhlestein JB, Anderson JL. Health effects of intermittent fasting: hormesis or harm? A systematic review. Am J Clin Nutr. 2015;102:464–70. https://doi.org/10.3945/ajcn.115.109553.CrossRefPubMed

92.

Seimon RV, Roekenes JA, Zibellini J, Zhu B, Gibson AA, Hills AP, et al. Do intermittent diets provide physiological benefits over continuous diets for weight loss? A systematic review of clinical trials. Mol Cell Endocrinol. 2015;418(Pt 2):153–72. https://doi.org/10.1016/j.mce.2015.09.014.CrossRefPubMed

93.

Pan H, Finkel T. Key proteins and pathways that regulate lifespan. J Biol Chem. 2017;292(16):6452–60. https://doi.org/10.1074/jbc.R116.771915.CrossRefPubMedPubMedCentral

94.

Hwangbo D-S, Lee H-Y, Abozaid LS, Min K-J. Mechanisms of lifespan regulation by calorie restriction and intermittent fasting in model organisms. Nutrients. 2020;12. https://doi.org/10.3390/nu12041194.

95.

Rajpal A, Ismail-Beigi F. Intermittent fasting and ‘metabolic switch’: effects on metabolic syndrome, prediabetes and type 2 diabetes. Diabetes Obes Metab. 2020:dom.14080. https://doi.org/10.1111/dom.14080.

96.

Muñoz-Hernández L, Márquez-López Z, Mehta R, Aguilar-Salinas CA. Intermittent fasting as part of the management for T2DM: from animal models to human clinical studies. Curr Diab Rep. 2020;20:13. https://doi.org/10.1007/s11892-020-1295-2.CrossRefPubMed

97.

Sharma A, Tate M, Mathew G, Vince JE, Ritchie RH, de Haan JB. Oxidative stress and NLRP3-inflammasome activity as significant drivers of diabetic cardiovascular complications: therapeutic implications. Front Physiol. 2018;9. https://doi.org/10.3389/fphys.2018.00114.

98.

Chen X, Guo X, Ge Q, Zhao Y, Mu H, Zhang J. ER stress activates the NLRP3 inflammasome: a novel mechanism of atherosclerosis. Oxidative Med Cell Longev. 2019;2019:3462530–18. https://doi.org/10.1155/2019/3462530.CrossRef

99.

Mastronuzzi T, Grattagliano I. Nutrition as a health determinant in elderly patients. Curr Med Chem. 2019;26:3652–61. https://doi.org/10.2174/0929867324666170523125806.CrossRefPubMed

100.

Pivovarova O, Hornemann S, Weimer S, Lu Y, Murahovschi V, Zhuk S, et al. Regulation of nutrition-associated receptors in blood monocytes of normal weight and obese humans. Peptides. 2015;65:12–9. https://doi.org/10.1016/j.peptides.2014.11.009.CrossRefPubMed

Titel: Nutrition and Diabetes in the Context of Inflammaging
verfasst von: Sandra Maria Lima Ribeiro
S. S. M. Fernandez
M. M. Rogero
Publikationsdatum: 09.11.2020
Verlag: Springer US
Erschienen in: Current Geriatrics Reports / Ausgabe 4/2020
Elektronische ISSN: 2196-7865
DOI: https://doi.org/10.1007/s13670-020-00338-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2020

Geriatric Vulvar Dermatology

Melanoma Diagnosis and Treatment in the Elderly

Cellulitis Mimics in the Geriatric Patient

Dietary Patterns, Diabetes, and Aging

Mobility in Acute Care for Geriatric Patients with Orthopedic Conditions: a Review of Recent Literature